1381 RESULTS
CONFERENCE COVERAGE 2004-07-27 Conference Coverage Brain imaging has emerged as perhaps the most promising source to date of an antecedent marker for Alzheimer's disease. Such a sought-after, tell-tale giveaway that the underlying process is marching along inexorably in people who
CONFERENCE COVERAGE 2004-07-23 Conference Coverage APP and presenilin mutations cause Alzheimer’s, tau mutations cause tauopathies, and α-synuclein mutations cause Parkinson’s, right? Well, yes, but it’s not nearly that simple. At the 9th International Conference on Alzheimer’s Disease
CONFERENCE COVERAGE 2004-07-22 Conference Coverage Perhaps…yes? At first blush, this is the tentative conclusion one must draw if the results of two presentations yesterday on the formal analysis of Elan’s AN-1792 vaccine are both right. The presentations were part of the 9th Internati
CONFERENCE COVERAGE 2004-07-21 Conference Coverage Of course mom was right; she always is. But for those who like evidence before they believe, consider this: At the Philadelphia conference, Francine Grodstein at Harvard Medical School presented data demonstrating that taking β-caroten
CONFERENCE COVERAGE 2004-07-19 Conference Coverage One of the field’s biggest hopes for a quick and easy new AD therapy received a punch in the stomach today as the 9th International Conference on Alzheimer’s Disease and Related Disorders got under way in Philadelphia. John Breitner, o
CONFERENCE COVERAGE 2004-07-07 Conference Coverage Gathering in Colorado’s Rocky Mountains, scientists from around the world discussed their independent research developments, only to realize that they have more in common than previously imagined. One in a series of FASEB Summer Resear
CONFERENCE COVERAGE 2004-06-15 Conference Coverage What, exactly, is the trigger for Alzheimer’s disease? Is there one such thing? At today’s annual meeting of the American Society for Biochemistry and Molecular Biology in Boston, Li Huei Tsai of Harvard Medical School presented data s
CONFERENCE COVERAGE 2004-05-27 Conference Coverage Two scientists updated the audience on the continuing workup of patients in Elan’s ill-fated phase II trial of the AN-1792 vaccine. James Nicoll recounted what he got to see firsthand from his perch as a research and diagnostic patholo
CONFERENCE COVERAGE 2004-05-26 Conference Coverage In the study of genetics, bursts of excitement alternate with periods of lulls. John Hardy, of NIH in Bethesda, took advantage of a present lull (i.e., no new genes on offer this time) to integrate current knowledge in neurodegeneratio
CONFERENCE COVERAGE 2004-05-26 Conference Coverage Unlike prion researchers, their colleagues in Alzheimer’s disease have a rich trove of current and potential future drug targets into which they can sink their collective investigative teeth. It is, of course, the APP processing proble
CONFERENCE COVERAGE 2004-05-24 Conference Coverage In the waning days of March, researchers from around the world met in St. Moritz to send off the cold season with three days of science and skiing amid the glorious scenery of the Engadine Alps, in one of Switzerland’s most beautiful v
CONFERENCE COVERAGE 2004-05-24 Conference Coverage Anthony Williamson, of the Scripps Research Institute, La Jolla, California, first noted that to make further inroads into the disease, the field sorely needed an atomic structure of PrPsc. He agreed with Weissmann and Aguzzi that one
CONFERENCE COVERAGE 2004-04-16 Conference Coverage Last month, the commercial conference planner IBC Screentech held a conference on drug development approaches in neurodegeneration in San Diego, California, as part of its World Summit series. Dora Kovacs, of Massachusetts General Hosp
CONFERENCE COVERAGE 2004-01-13 Conference Coverage This report summarizes some of the genetic findings for late-onset Alzheimer's disease presented last November at the 33rd Annual Meeting of the Society for Neuroscience in New Orleans. It covers recent progress in identifying the
CONFERENCE COVERAGE 2003-12-24 Conference Coverage Scientists prospecting the amyloid hypothesis for new treatment strategies have set their sights on the idea of boosting the enzymatic destruction of the Aβ peptide. A flurry of recent papers and presentations at the 33rd Annual Meetin
